Expertise in

conditions

Olivier Hermine

Paris, FR

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Paris, FR

Overview

Olivier Hermine practices practicing medicine in Paris, France.

Mr. Hermine is highly rated in 67 conditions, according to our data. His clinical expertise encompasses Mast Cell Activation Syndrome (MCAS), Mantle Cell Lymphoma (MCL), Systemic Mastocytosis, Bone Marrow Transplant, and Splenectomy.

He is actively involved in clinical research, co-authoring 644 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Paris, France

Other Locations

Boulogne-billancourt, France

Marseille, France

INSERM U955, Paris Est Créteil University, Creteil, France

Lille, France

Lyon, France

France

Clichy-sous-bois, France

Montpellier, France

24 Boulevard De Montparnasse, 75015 Paris, 24 Boulevard De Montparnasse, 75015 Paris, 75015 Paris, 149 Rue De Sèvres 75015 Paris, France [5], Sevres, 75015, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Enrollment Status: Recruiting

Publish Date: May 22, 2026

Intervention Type: Drug

Study Drug: BLU-263

Study Phase: Phase 2/Phase 3

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Enrollment Status: Completed

Publish Date: April 24, 2026

Intervention Type: Drug

Study Drug: Avapritinib

Study Phase: Phase 2

Evaluation of Basal Tryptasemia According to Age in a Pediatric Control Population

Enrollment Status: Completed

Publish Date: September 12, 2025

Intervention Type: Other

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC

Enrollment Status: Completed

Publish Date: August 02, 2024

Intervention Type: Other

Study Phase: Not Applicable

Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable

Enrollment Status: Completed

Publish Date: February 02, 2024

Intervention Type: Drug

Study Drug: Gemtuzumab ozogamicin

Study Phase: Phase 2/Phase 3

Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission

Enrollment Status: Terminated

Publish Date: October 14, 2021

Intervention Type: Drug, Procedure

Study Phase: Phase 3

Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.

Enrollment Status: Completed

Publish Date: July 05, 2019

Intervention Type: Drug

Study Phase: Phase 2

Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)

Enrollment Status: Unknown

Publish Date: January 10, 2018

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

View 7 Less Clinical Trials

641 Total Publications

The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa).

Journal: American journal of hematology

Published: May 20, 2026

View All 641 Publications

Frequently Asked Questions about Olivier Hermine

Is Olivier Hermine a top-rated expert for Mast Cell Activation Syndrome (MCAS)?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier Hermine is classified as an Elite expert for Mast Cell Activation Syndrome (MCAS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier Hermine participate in research or clinical trials?

Yes. Olivier Hermine has published 641 articles and abstracts on conditions like Mast Cell Activation Syndrome (MCAS). You can view a list of Olivier Hermine's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hermine's expertise for a condition

ConditionClose